NCI - National Cancer Institute
Abstract Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC) brings mulƟdisciplinary research teams with experƟse in translaƟonal sciences along with streamlined resources, efficient services, and an insƟtuƟonal environment that fosters innovaƟve clinical and translaƟonal research to the NaƟonal Clinical Trial Network (NCTN). IUSCCC invesƟgators have led trials that defined the standard of care in thymoma, testes, pancreas, and breast cancer. We are commiƩed to leading and supporƟng the next generaƟon of translaƟonal trials within the NCTN. As a Lead Academic ParƟcipaƟng Site we will pursue six specific aims: 1)Integrate genomics, pharmacogenomics, and other molecular assays with tradiƟonal histopathology and imaging to individualize therapy, 2)Lead clinical and translaƟonal research in key rare tumors, 3)Share immunology experƟse across the NCTN, 4)Ensure that all paƟents benefit from the NCTN, 5)Lend experƟse to NCTN operaƟonal efficiency iniƟaƟves, and 6)Mentor junior faculty members to lead the next generaƟon of translaƟonal clinical trials. To accomplish those specific aims, we employ a coordinated clinical trial infrastructure that is efficient and cost-effecƟve, meeƟng the needs of invesƟgators from iniƟal study concept through compleƟon and reporƟng. Overall leadership of the NCTN at IUSCCC is vested in Dr. Kathy Miller, a seasoned invesƟgator who has led three naƟonal trials coordinated by ECOG-ACRIN and recently completed two terms as Co-Chair of the NCI Breast Cancer Steering CommiƩee. Dr. Miller enjoys widespread insƟtuƟonal and mulƟdisciplinary support and is fully empowered to leverage resources to increase accrual and movement of IUSCCC translaƟonal science forward to the NCTN. She is joined in leadership by key invesƟgators in Gynecologic and RadiaƟon Oncology. In this applicaƟon IU will be joined by one affiliate, the Richard A Roudebush VA Medical Center. IUSCCC contributed ~50 paƟents over the most recent 5- year period (3/2019-9/2024) to NCTN; accrual has increased since the pandemic-decline with 79 paƟents enrolled in 2024. Accrual has been evenly split between trials sponsored by ECOG-ACRIN and NRG, together accounƟng for ~80% of our total. In addiƟon, IUSCCC invesƟgators have held key leadership roles within ECOG and the NRG and have made key scienƟfic contribuƟons employing biologic specimens banked as part of cooperaƟve group trials.
Up to $367K
2032-02-29
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
One-time $749 fee · Includes AI drafting + templates + PDF export
Dynamic Cognitive Phenotypes for Prediction of Mental Health Outcomes in Serious Mental Illness
NIMH - National Institute of Mental Health — up to $18.3M
COORDINATED FACILITIES REQUIREMENTS FOR FY25 - FACILITIES TO I
NCI - National Cancer Institute — up to $15.1M
Leveraging Artificial Intelligence to Predict Mental Health Risk among Youth Presenting to Rural Primary Care Clinics
NIMH - National Institute of Mental Health — up to $15.0M
Feasibility of Genomic Newborn Screening Through Public Health Laboratories
OD - NIH Office of the Director — up to $14.4M
WOMEN'S HEALTH INITIATIVE (WHI) CLINICAL COORDINATING CENTER - TASK AREA A AND A2
NHLBI - National Heart Lung and Blood Institute — up to $10.2M
Metal Exposures, Omics, and AD/ADRD risk in Diverse US Adults
NIA - National Institute on Aging — up to $10.2M